Lineage Cell Therapeutics (LCTX) EBT Margin (2010 - 2026)
Lineage Cell Therapeutics posted quarterly EBT Margin of 416.7% for Q1 2026, down 1543.0% year-on-year from 28.88% in Q1 2025, and down 270.32% on a QoQ basis from 244.66% in Q4 2025.
Lineage Cell Therapeutics (LCTX) has 17 years of EBT Margin data on file, last reported at 416.7% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 1543.0% year-over-year to 416.7%; the trailing twelve-month figure through Mar 2026 stood at 93.15% (up 9572.0% YoY), and the FY2025 full-year result was 471.61%, down 27599.0% from the prior year.
- EBT Margin for Q1 2026 stood at 416.7%, down from 244.66% in the prior quarter.
- Across five years, EBT Margin topped out at 244.66% in Q4 2025 and bottomed at 698.95% in Q2 2025.
- The 5-year median for EBT Margin is 225.77% (2023), against an average of 261.55%.
- The widest annual swing landed in 2022, when EBT Margin soared 82077 bps; it then plunged 38852 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 332.22% in 2022, then jumped by 32 bps to 225.77% in 2023, then soared by 50 bps to 113.32% in 2024, then jumped by 316 bps to 244.66% in 2025, then plunged by 270 bps to 416.7% in 2026.
- The last three EBT Margin figures came in at 416.7% (Q1 2026), 244.66% (Q4 2025), and 92.91% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | Lineage Cell Therapeutics | 325.89 Mn | 261.99 Mn | 1.73 Mn | -416.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -416.70% |
| Dec 31, 2025 | 244.66% |
| Sep 30, 2025 | -92.91% |
| Jun 30, 2025 | -698.95% |
| Mar 31, 2025 | -401.26% |
| Dec 31, 2024 | -113.32% |
| Sep 30, 2024 | -79.41% |
| Jun 30, 2024 | -410.01% |
| Mar 31, 2024 | -454.16% |
| Dec 31, 2023 | -225.77% |
| Sep 30, 2023 | -574.48% |
| Jun 30, 2023 | -161.33% |
| Mar 31, 2023 | -260.14% |
| Dec 31, 2022 | -332.22% |
| Sep 30, 2022 | -185.96% |
| Jun 30, 2022 | -148.96% |
| Mar 31, 2022 | -135.44% |
| Dec 31, 2021 | -56.02% |
| Sep 30, 2021 | -389.69% |
| Jun 30, 2021 | -969.73% |
| Mar 31, 2021 | -370.33% |
| Dec 31, 2020 | 277.18% |
| Sep 30, 2020 | -1,392.29% |
| Jun 30, 2020 | -1,691.71% |
| Mar 31, 2020 | -1,639.69% |
| Dec 31, 2019 | -430.30% |
| Sep 30, 2019 | -3,087.48% |
| Jun 30, 2019 | -4,017.97% |
| Mar 31, 2019 | 3,762.07% |
| Dec 31, 2018 | -5,980.21% |
| Sep 30, 2018 | 6,776.37% |
| Jun 30, 2018 | -182.41% |
| Mar 31, 2018 | -9,086.73% |
| Dec 31, 2017 | -8,131.64% |
| Sep 30, 2017 | 1,146.58% |
| Jun 30, 2017 | -4,282.98% |
| Mar 31, 2017 | 15,285.59% |
| Dec 31, 2016 | -701.72% |
| Sep 30, 2016 | 2,030.88% |
| Jun 30, 2016 | 1,812.55% |
| Mar 31, 2016 | -1,298.54% |
| Dec 31, 2015 | -1,372.59% |
| Sep 30, 2015 | -943.92% |
| Jun 30, 2015 | -758.55% |
| Mar 31, 2015 | -1,376.70% |
| Dec 31, 2014 | -900.96% |
| Sep 30, 2014 | -1,277.50% |
| Jun 30, 2014 | -1,509.59% |
| Mar 31, 2014 | -1,184.71% |
| Dec 31, 2013 | -1,756.63% |
| Sep 30, 2013 | -2,021.41% |
| Jun 30, 2013 | -791.45% |
| Mar 31, 2013 | -1,947.67% |
| Dec 31, 2012 | -662.50% |
| Sep 30, 2012 | -713.17% |
| Jun 30, 2012 | -640.10% |
| Mar 31, 2012 | -936.08% |
| Dec 31, 2011 | -333.87% |
| Sep 30, 2011 | -370.27% |
| Jun 30, 2011 | -659.25% |
| Mar 31, 2011 | -488.45% |
| Dec 31, 2010 | -332.97% |
| Sep 30, 2010 | -2,264.68% |